Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
A decade in the making: How functional NAMs are redefining cardiac safety assessment
In recent years, the pharmaceutical industry has witnessed a dramatic acceleration in the adoption of New Approach Methodologies (NAMs) for…
Read More
GLP-1 Blockbusters Propel Pharma R&D Returns to 7%, Masking Broader Productivity Challenges, Deloitte Report Reveals
After a prolonged period where growth remained uneven in the wake of global disruptions, a pivotal metric for biopharma research…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The U.S. Food and Drug Administration (FDA) launched its Commissioner’s National Priority Voucher (CNPV) pilot program in June 2025, an…
Read More
BioNTech’s Meteoric Rise from Pandemic Savior to Oncology Powerhouse Undergoes Radical Restructuring and Job Cuts
Mainz, Germany — BioNTech SE, the German biotechnology firm that achieved global recognition for its pivotal role in developing the…
Read More
EClinical Solutions Study Models 241% ROI from AI-Powered Clinical Trial Data Platform
The landscape of clinical trials, a critical yet notoriously complex phase in drug development, is on the cusp of a…
Read More
Protecting innovation in a borderless pharma economy: The reality of globalized pharma innovation
Modern pharmaceutical drug development programs are intrinsically global, spanning continents and leveraging distributed expertise. From the initial discovery of a…
Read More
Novo Nordisk Transfers Parkinson’s Cell Therapy to Cellular Intelligence, Signaling New Era for AI-Driven Biopharma
In a significant development for the burgeoning field of cell therapy and artificial intelligence in drug discovery, Cellular Intelligence, a…
Read More
Marty Makary Resigns as FDA Commissioner Amid Intensifying Administrative Pressure and Policy Conflicts
Marty Makary resigned on Tuesday as commissioner of the Food and Drug Administration, effective immediately, following weeks of escalating speculation…
Read More
Canada approves generic semaglutide from Dr. Reddy’s, a G7 first enabled by Novo Nordisk’s lapsed CAD$250 patent
The pharmaceutical landscape for diabetes and weight management medications has undergone a significant shift with Health Canada’s authorization of Dr.…
Read More
